Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Piroxicam

Drug and asset intelligence for Piroxicam with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
3
Catalysts
2
Stage
Development stage unavailable

Sponsor company

Strides Pharma →

Recent signals(3)

RegulatoryAugust 6, 2026

FDA Grants AP Status for Piroxicam ANDA206152 by Micro Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status of 'AP' for Piroxicam submitted by Micro Labs.

RegulatoryJuly 1, 2026

Strides Pharma's Piroxicam ANDA206136 Receives AP Status from FDA

Strides Pharma's ANDA for Piroxicam has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 1, 2026

FDA Grants AP Status for Piroxicam ANDA210347 by Strides Pharma

Strides Pharma has received an Abbreviated New Drug Application (ANDA) approval for Piroxicam.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Piroxicam

July 1, 2026 · N/A

Topline Data

— Piroxicam

July 1, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

NSAID →
Pain Management →
Pain Management · NSAID →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.